AI
AXSM icon

Atria Investments’s Axsome Therapeutics AXSM Stock Holding History

Atria Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Sell
1,375
-288
-17% -$49.7K ﹤0.01% 1899
2025
Q4 		$304K Sell
1,663
-106
-6% -$14.8K ﹤0.01% 1730
2025
Q3 		$215K Buy
+1,769
New +$199K ﹤0.01% 1907

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atria Investments's AXSM Position: Q1 2026 in Review

Atria Investments reduced its Axsome Therapeutics (AXSM) stake by 17% in Q1 2026, selling an estimated $49.7K and leaving 1,375 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Atria Investments first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $304K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Atria Investments held 1,375 shares of Axsome Therapeutics worth $232K as of Q1 2026.
  • Atria Investments sold 288 Axsome Therapeutics shares in Q1 2026, an estimated $49.7K.
  • Axsome Therapeutics made up ﹤0.01% of Atria Investments's portfolio in Q1 2026, its #1899 holding.
  • Atria Investments first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Atria Investments's Axsome Therapeutics position peaked at $304K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.